Clinical outcomes of lung-transplant recipients treated by voriconazole and caspofungin combination in aspergillosis

Journal of Clinical Pharmacy and Therapeutics

Volumn 35, Issue 1, 2010, Pages 49-53

  Thomas, A ^a   Korb, V ^a   Guillemain, R ^a   Caruba, T ^a   Boussaud, V ^a   Billaud, E ^a   Prognon, P ^a   Begue D ^a,b   Sabatier, B ^a  

^a HÔPITAL EUROPÉEN GEORGES POMPIDOU   (France)

^b FACULTÉ DES SCIENCES PHARMACEUTIQUES ET BIOLOGIQUES   (France)

Author keywords

Antifungal combination; Caspofungin; Invasive pulmonary aspergillosis; Lung transplantation; Voriconazole

Indexed keywords

ALKALINE PHOSPHATASE; CASPOFUNGIN; TACROLIMUS; VORICONAZOLE;

ADOLESCENT; ADULT; ALKALINE PHOSPHATASE BLOOD LEVEL; ARTICLE; ASPERGILLUS FLAVUS; ASPERGILLUS FUMIGATUS; CHOLESTASIS; CLINICAL ARTICLE; CONTROLLED STUDY; CYSTIC FIBROSIS; DOSE TIME EFFECT RELATION; DRUG BLOOD LEVEL; DRUG WITHDRAWAL; FEMALE; HALLUCINATION; HUMAN; LIVER TOXICITY; LUNG ASPERGILLOSIS; LUNG TRANSPLANTATION; MALE; OUTCOME ASSESSMENT; POSTOPERATIVE INFECTION; RETROSPECTIVE STUDY; SIDE EFFECT;

ADOLESCENT; ADULT; ANTIFUNGAL AGENTS; ASPERGILLUS; CYSTIC FIBROSIS; DRUG INTERACTIONS; DRUG THERAPY, COMBINATION; ECHINOCANDINS; FEMALE; HUMANS; IMMUNOCOMPROMISED HOST; IMMUNOSUPPRESSIVE AGENTS; INVASIVE PULMONARY ASPERGILLOSIS; LUNG TRANSPLANTATION; MALE; MIDDLE AGED; PYRIMIDINES; RETROSPECTIVE STUDIES; TACROLIMUS; TREATMENT OUTCOME; TRIAZOLES; YOUNG ADULT;

EID: 74349130637     PISSN: 02694727     EISSN: 13652710     Source Type: Journal    
DOI: 10.1111/j.1365-2710.2009.01061.x     Document Type: Article

References (15)

1. Lin SJ, Schranz J, Teutsch SM (2001) Aspergillosis case-fatality rate: systematic review of the literature. Clinical Infectious Diseases, 32, 358 366.
2. Herbrecht R, Denning DW, Patterson TF et al. (2002) Voriconazole versus amphotericin B for primary therapy of invasive aspergillosis. New England Journal of Medicine, 347, 408 415. (Pubitemid 34851833)
3. Marr KA, Boeckh M, Carter RA, Kim HW, Corey L (2004) Combination antifungal therapy for invasive aspergillosis. Clinical Infectious Disease, 39, 797 802.
4. Krishnan-Natesan S, Chandrasekar PH (2008) Current and future therapeutic options in the management of invasive aspergillosis. Drugs, 68, 265 282.
5. Trifilio S, Pennick G, Pi J et al. (2007) Monitoring plasma voriconazole levels may be necessary to avoid subtherapeutic levels in hematopoietic stem cell transplant recipients. Cancer, 109, 1532 1535.
6. Pascual A, Calandra T, Bolay S, Buclin T, Bille J, Marchetti O (2008) Voriconazole therapeutic drug monitoring in patients with invasive mycoses improves efficacy and safety outcomes. Clinical Infectious Diseases, 46, 201 211.
7. Ascioglu S, Rex JH, de Pauw B et al. (2002) Defining opportunistic invasive fungal infections in immunocompromised patients with cancer and hematopoietic stem cell transplants: an international consensus. Clinical Infectious Diseases, 34, 7 14.
8. Vazquez JA (2008) Combination antifungal therapy for mold infections: much ado about nothing? Clinical Infectious Diseases, 46, 1889 1901.
9. Petraitis V, Petraitiene R, Sarafandi AA et al. (2003) Combination therapy in treatment of experimental pulmonary aspergillosis: synergistic interaction between an antifungal triazole and an echinocandin. Journal of Infectious Diseases, 187, 1834 1843.
10. Caillot D, Thiébaut A, Herbrecht R et al. (2007) Liposomal amphotericin B in combination with caspofungin for invasive aspergillosis in patients with hematologic malignancies: a randomized pilot study (Combistrat trial). Cancer, 110, 2740 2746.
11. Singh N, Limaye AP, Forrest G et al. (2006) Combination of voriconazole and caspofungin as primary therapy for invasive aspergillosis in solid organ transplant recipients: a prospective, multicenter, observational study. Transplantation, 81, 320 326.
12. Silveira FP, Husain S (2008) Fungal infections in lung transplant recipients. Current Opinion in Pulmonary Medicine, 14, 211 218.
13. Rey E, Treluyer JM, Pons G (1998) Drug disposition in cystic fibrosis. Clinical Pharmacokinetics, 35, 313 329.
14. Touw DJ (1998) Clinical pharmacokinetics of antimicrobial drugs in cystic fibrosis. Pharmacy World and Science, 20, 149 160.
15. Walsh TJ, Anaissie EJ, Denning DW et al. (2008) Treatment of aspergillosis: clinical practice guidelines of the Infectious Diseases Society of America. Clinical Infectious Diseases, 46, 327 360.